LLY - Eli Lilly and Company

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $1,315.42 DETAILS

Stock News

Eli Lilly, Dell Among Stocks To Watch As Market Leadership Shifts

As AI-related stocks weaken, investors are rotating into other sectors, such as energy and health care.

Jul 25, 2026 04:00 AM • investors.com

This Catalyst Makes Eli Lilly a Top Growth Stock in 2026

Eli Lilly (NYSE:LLY | LLY Price Prediction) has accelerated despite its $1 trillion scale.

Jul 24, 2026 09:30 AM • 247wallst.com

LLY's Retatrutide Nears 2027 Filing With Two More Phase III Wins

Eli Lilly's retatrutide meets the primary endpoint in the phase III TRIUMPH-2 & TRIUMPH-3 studies, supporting planned regulatory submissions for obesity in 2027.

Jul 24, 2026 07:16 AM • zacks.com

As Lilly and Novo Clash in Court, Wall Street Is Eyeing This Bigger Prize

The legal battle between Novo Nordisk and Eli Lilly is escalating, but analysts are more focused on developments in the lab.

Jul 24, 2026 05:09 AM • barrons.com

Novo Nordisk Seeks Injunction Against Eli Lilly in Dispute Over Weight-Loss Ads

Friday's preliminary injunction request escalates legal proceedings initiated earlier this week.

Jul 24, 2026 01:48 AM • wsj.com

Novo Nordisk seeks preliminary injunction against Lilly weight-loss ads

Novo Nordisk said on Friday it is seeking a preliminary U.S. court injunction to immediately block obesity ‌and diabetes drug advertisements by Eli Lilly , in a further escalation of the rivalry between the two groups.

Jul 24, 2026 12:41 AM • reuters.com

2 Top Growth Stocks to Buy Right Now Without Any Hesitation

There are plenty of reasons to love these companies.

Jul 23, 2026 08:30 PM • fool.com

Lilly's Next-Generation Obesity Shot Clears Another Hurdle

Eli Lilly & Co.'s next-generation weight-loss shot retatrutide didn't increase overall heart risk in a new study, helping dispel concerns over its potential. The company plans to file for US Food and Drug Administration approval early next year, later than investors hoped, due to the complexity of the approval pathway.

Jul 23, 2026 03:25 PM • youtube.com

There's A Hidden Gem In Eli Lilly's Weight-Loss News — And It Could Slam Compounders

Eli Lilly said Thursday it will delay filing for FDA approval of its next-gen weight-loss drug, retatrutide, until the first quarter.

Jul 23, 2026 09:38 AM • investors.com

Eli Lilly Will File For Retatrutide Approval—As Study Shows Average Weight Loss Of 56 Pounds

Analysts have suggested retatrutide could become a blockbuster weight loss drug if approved. In January, TD Cowen analysts estimated retatrutide could generate $3.8 billion in sales in 2030, while GlobalData forecasts sales of $15.6 billion by 2031.

Jul 23, 2026 06:15 AM • forbes.com

Which Is the Better Healthcare ETF: First Trust's High-Conviction FBT or Vanguard's Low-Cost VHT?

FBT surged 51.6% in one year but carries higher risk and costs. VHT offers broader diversification at a fraction of the expense ratio.

Jul 23, 2026 04:15 AM • fool.com

Eli Lilly Preparing Retatrutide Applications After Positive Weight-Loss Data

Eli Lilly is preparing application materials for its next-generation weight-loss drug, retatrutide, following data from two Phase 3 trials showing the treatment delivered substantial results.

Jul 23, 2026 02:48 AM • wsj.com

Lilly announces more next-gen obesity drug data, plans Q1 2027 FDA application

Eli Lilly ‌on Thursday said two more Phase 3 trials of its experimental obesity drug retatrutide showed positive results and it plans to submit an application to the U.S. Food and Drug Administration in the first quarter of next year.

Jul 23, 2026 02:47 AM • reuters.com

Eli Lilly says it will file for approval of next-generation obesity drug in 2027 as it clears two more trials

Eli Lilly said it will file for approval of its next-generation obesity drug, retatrutide, in the first quarter of 2027, as it succeeds in two more late-stage trials. The drug delivered significant weight loss and improvements in a key measure of blood sugar levels in adults with obesity and either Type 2 diabetes or established cardiovascular disease.

Jul 23, 2026 02:45 AM • cnbc.com

Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C

In TRIUMPH-2, adults with obesity or overweight and type 2 diabetes, a population with increased difficulties losing weight, lost up to an average of 49.6 lbs (20.8%) at 80 weeks In TRIUMPH-3, adults with severe obesity and established cardiovascular disease, with or without type 2 diabetes, lost up to an average of 55.8 lbs (22.6%) at 80 weeks Lilly plans to submit a Biologics License Application (BLA) for retatrutide to FDA in Q1 2027 INDIANAPOLIS, July 23, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY), the maker of Zepbound (tirzepatide) and Foundayo (orforglipron), today announced positive topline results from TRIUMPH-2 and TRIUMPH-3, two pivotal Phase 3 trials evaluating retatrutide, an investigational, first-in-class GIP, GLP-1, and glucagon triple hormone receptor agonist. In both studies, retatrutide met the primary endpoint, delivering substantial weight loss in adults with obesity and some of its most serious complications: type 2 diabetes and established cardiovascular disease.

Jul 23, 2026 02:45 AM • prnewswire.com

Nomura Core Equity Fund Q2 2026 Portfolio Review

Seagate Technology shares continued to advance as demand for high-capacity storage tied to AI data-center buildouts supported further positive earnings revisions. On balance, the Fund's artificial intelligence positioning was a net positive contributor to relative performance during the quarter. We added the Humana position on the view that earnings are at a cyclical trough, with MA margins currently depressed, in some cases negative, as elevated medical cost trends have outpaced premium growth across the industry.

Jul 22, 2026 08:35 AM • seekingalpha.com

The Obesity Drug War Turns Ugly: Novo Nordisk Sues Eli Lilly and Wall Street Already Picked a Side

The polite duopoly running the modern weight-loss drug boom just filed for divorce, and the market voted before the ink dried.

Jul 22, 2026 08:25 AM • 247wallst.com

Lilly confirms date and conference call for second-quarter 2026 financial results announcement

INDIANAPOLIS, July 22, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will announce its second-quarter 2026 financial results on August 5, 2026. Lilly will also conduct a conference call that day with the investment community and media to further detail the company's financial performance.

Jul 22, 2026 06:00 AM • prnewswire.com

PINK vs. IXJ: Which Health Care ETF Is the Better Buy for Investors?

PINK has stronger one-year and three-year returns, while IXJ offers lower costs and a higher dividend yield.

Jul 22, 2026 02:45 AM • fool.com

These major drug stocks rally after Trump's zero tariff announcement

President Donald Trump has announced that all generic drugs imported into the United States would continue to enjoy a zero-percent tariff for another two years, sending major drug stocks up.

Jul 22, 2026 02:31 AM • finbold.com